5,220 Shares in RxSight, Inc. (NASDAQ:RXST) Bought by Arista Wealth Management LLC

Arista Wealth Management LLC acquired a new position in shares of RxSight, Inc. (NASDAQ:RXST) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 5,220 shares of the company’s stock, valued at approximately $258,000.

A number of other large investors have also recently bought and sold shares of the company. CWM LLC boosted its position in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of RxSight by 854.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares during the last quarter. Quest Partners LLC acquired a new stake in RxSight in the second quarter valued at about $41,000. Larson Financial Group LLC bought a new position in RxSight in the first quarter valued at about $51,000. Finally, Amalgamated Bank lifted its holdings in shares of RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after acquiring an additional 207 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at RxSight

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $53.19, for a total value of $164,889.00. Following the completion of the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,247,064.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 43,415 shares of company stock worth $2,178,847 in the last 90 days. Corporate insiders own 9.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on RXST shares. Stifel Nicolaus lowered their price objective on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Wells Fargo & Company lowered their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Oppenheimer lowered their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Finally, BTIG Research lifted their price target on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $61.63.

RxSight Stock Up 0.3 %

RXST opened at $51.25 on Tuesday. The stock has a market cap of $1.90 billion, a PE ratio of -50.25 and a beta of 1.19. RxSight, Inc. has a twelve month low of $22.91 and a twelve month high of $66.54. The company has a fifty day moving average of $51.56 and a 200-day moving average of $53.59.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. The firm had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The business’s quarterly revenue was up 67.6% on a year-over-year basis. During the same period last year, the company posted ($0.40) EPS. Sell-side analysts anticipate that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.